Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Jan 15, 2023 6:20pm
110 Views
Post# 35224513

RE:RE:Aside from share price ... smells right for some bolt-ons

RE:RE:Aside from share price ... smells right for some bolt-onsYou are correct.
This is definitely what you'd define as a value trap.
Has always been like that.
Even the bolt-ons likely won't offer real value from a share price perspective.
But they eventually will happen and the value trap will continue.

It took 19 years to become a success the first time - filled with years you'd define as "value trap."
I wouldn't bet on when - but I'd expect to beat 19 years this time around.

the 60+ people who control 70% of the business don't care about the trading price - most are not selling anyway.  They're building a pharma and making sure no one gets in the way.

Eventually - this gets the attention of serious interest and additional accumulators.
Eventually there's demand for these shares.

But, I think the main business still has a lot of maturing to do.
Long way to go. 

Don't hold me to it - just what I've always believed.

This thing moves sideway until it doesn't anymore ... that's exactly how it's designed - fully controlled by a few owners.



<< Previous
Bullboard Posts
Next >>